FDA Approved: IMPAVIDO — Supplemental Application (Profounda, Inc.)

View source ↗

Summary

FDA approved a supplemental application for IMPAVIDO (miltefosine) from Profounda, Inc. under NDA204684, expanding its approved use. This action updates the dru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis
• Visceral Leishmaniasis

Drugs mentioned

• Impavido (miltefosine)

Snippet

SUPPL AP for IMPAVIDO (MILTEFOSINE)